News and Press Releases
DRUG DISCOVERY 2024: CONNECTING MINDS, TRANSFORMING SCIENCE, EMPOWERING COMMUNITY
We are proud to be media partners of ELRIG's Drug Discovery 2024! Europe’s largest conference for the drug discovery community returns to London, with scientific tracks covering not only therapeutic...
Category: Drug Discovery
Posted: August 29, 2024
ELRIG (UK) Ltd. Salisbury House, Station Road, Cambridge, CB1 2LA, UK
European Commission Approves Astellas’ PADCEVTM (enfortumab vedotin) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer
First regimen approved in advanced urothelial cancer to demonstrate superiority to platinum-containing chemotherapy, the standard of care for nearly 40 years European Marketing Authorization based on positive overall survival and...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: August 28, 2024
European Commission approves RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer after failure of prior therapy
Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, have until now faced a poor prognosis and limited treatment options after disease progression on...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: August 27, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
European Commission approves BALVERSA®▼ (erdafitinib) for adult patients with unresectable or metastatic urothelial carcinoma
First pan FGFR kinase inhibitor to be approved in the European Economic Area, for adults with unresectable or metastatic urothelial carcinoma and susceptible FGFR3 alterations Approval based on THOR results,...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: August 23, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Cumulus Oncology and leadXpro Achieve Critical Milestone in GPR68 Drug Discovery Project
Small Molecules Identified for Therapeutic Intervention in Oncology and Inflammation Edinburgh, Scotland, and Villigen, Switzerland, 20 August 2024 – Cumulus Oncology, Europe’s first oncology-focused biotech creation company, announces that, in...
Category: Drug Discovery
Posted: August 22, 2024
CHMP recommends RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) after failure of prior therapy
Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, currently face a poor prognosis and limited treatment options after disease progression on osimertinib1,2,3,4 ...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: July 26, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Deuterium Depletion Is the Key to Getting a Breakthrough in Cancer Therapy
Two review papers consolidate 30 years of research BUDAPEST, Hungary, July 25, 2024 / Biotech Newswire / -- HYD LLC for Cancer Research and Drug Development (HYD or the Company)...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: July 25, 2024
ViroCell Biologics signs Master Services Agreement with prominent NCI-designated cancer centre
MSA enables collaboration on full suite of ViroCell’s viral vector manufacturing services to accelerate the cancer centre’s clinical development of novel gene-modified cell therapies Agreement follows ViroCell’s successful GMP manufacture...
Category: Biotechnology, Drug Discovery, Pharmaceutical
Posted: July 22, 2024
Evotec and Pfizer collaborate to advance drug discovery in France
Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases 11 July 2024, Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:...
Category: Drug Discovery
Posted: July 11, 2024
Just – Evotec Biologics, Inc. 401 Terry Avenue North Seattle, WA 98109, US
Pan Cancer T secures €4.25m in Seed Extension Round to advance next-generation T cell therapies
July 11 2024, Rotterdam, the Netherlands – Pan Cancer T B.V., a pioneering biotech start-up developing next-generation T cell therapies for solid cancer treatment, has successfully closed a €4.25m Seed...
Category: Drug Delivery
Posted: July 11, 2024
Concr launches trial using digital twins for outcome prediction in breast cancer
10 July 2024, London United Kingdom – Concr announces that first patients have been recruited to the VISION trial, an observational clinical study evaluating Concr’s therapeutic response predictive algorithm defining...
Category: Biotechnology
Posted: July 10, 2024
Epsilogen announces CTA approval for phase 1b trial of MOv18 IgE in platinum-resistant ovarian cancer
Phase 1b study expected to initiate in H2 2024 Previously reported phase 1 results showed MOv18 IgE to be safe and well-tolerated, with evidence of anti-tumour activity. 8 July 2024...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: July 8, 2024
Stockholm 3 commercially available in the US
A3P Biomedical AB, a leading Swedish diagnostics company specializing in advanced prostate cancer diagnostics, and BioAgilytix, a global bioanalytical services provider, are excited to announce that Stockholm3 for early detection...
Category: Biotechnology
Posted: July 3, 2024
Mission Therapeutics awarded $5.2m from The Michael J Fox Foundation and Parkinson’s UK to advance potential disease-modifying treatment MTX325
Investment will support investigation of Mission’s small molecule drug MTX325 in patients with early-stage Parkinson’s disease Marks latest step in Mission’s relationship with The Michael J Fox Foundation (MJFF), after...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: July 2, 2024
Moneta (Building 280), Babraham Research Campus, Cambridge, CB22 3AT, United Kingdom
RYBREVANT (amivantamab) in combination with chemotherapy is the first therapy approved by the European Commission for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations
Approval is supported by the phase 3 PAPILLON study, which showed amivantamab plus chemotherapy significantly reduced the risk of disease progression or death by 60% compared to chemotherapy alone 28...
Category: Clinical Trials, Pharmaceutical
Posted: June 28, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
